From what we know about the variants of concern, they affect the sequence coding for the spike protein. This could change the binding affinity of the virus to the ACE2 receptor and the binding affinity to antibodies. These could alter infectivity and severity of illness. But they are not likely to affect responsiveness to apabetalone. If ABL cures disease fromone variant it should do so with all of them.